No Data
No Data
Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress